Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.73
PRGO's Cash to Debt is ranked lower than
68% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. PRGO: 0.73 )
Ranked among companies with meaningful Cash to Debt only.
PRGO' s 10-Year Cash to Debt Range
Min: 0  Med: 0.22 Max: 18.37
Current: 0.73
0
18.37
Equity to Asset 0.59
PRGO's Equity to Asset is ranked lower than
55% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PRGO: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
PRGO' s 10-Year Equity to Asset Range
Min: 0.34  Med: 0.56 Max: 0.75
Current: 0.59
0.34
0.75
F-Score: 5
Z-Score: 3.23
M-Score: -2.66
WACC vs ROIC
5.98%
5.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.04
PRGO's Operating margin (%) is ranked higher than
77% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. PRGO: 17.04 )
Ranked among companies with meaningful Operating margin (%) only.
PRGO' s 10-Year Operating margin (%) Range
Min: -32.27  Med: 9.69 Max: 19.18
Current: 17.04
-32.27
19.18
Net-margin (%) 4.83
PRGO's Net-margin (%) is ranked lower than
54% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. PRGO: 4.83 )
Ranked among companies with meaningful Net-margin (%) only.
PRGO' s 10-Year Net-margin (%) Range
Min: -34.47  Med: 5.33 Max: 12.66
Current: 4.83
-34.47
12.66
ROE (%) 2.25
PRGO's ROE (%) is ranked lower than
64% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. PRGO: 2.25 )
Ranked among companies with meaningful ROE (%) only.
PRGO' s 10-Year ROE (%) Range
Min: -62.64  Med: 11.37 Max: 25.88
Current: 2.25
-62.64
25.88
ROA (%) 1.37
PRGO's ROA (%) is ranked lower than
61% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. PRGO: 1.37 )
Ranked among companies with meaningful ROA (%) only.
PRGO' s 10-Year ROA (%) Range
Min: -28.65  Med: 5.89 Max: 11.48
Current: 1.37
-28.65
11.48
ROC (Joel Greenblatt) (%) 45.41
PRGO's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. PRGO: 45.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70.38  Med: 27.31 Max: 53.06
Current: 45.41
-70.38
53.06
Revenue Growth (3Y)(%) 6.00
PRGO's Revenue Growth (3Y)(%) is ranked higher than
51% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PRGO: 6.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRGO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.5  Med: 7.15 Max: 17.5
Current: 6
-5.5
17.5
EBITDA Growth (3Y)(%) 8.10
PRGO's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 482 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.40 vs. PRGO: 8.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRGO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -25.1  Med: 25.50 Max: 40.1
Current: 8.1
-25.1
40.1
EPS Growth (3Y)(%) -21.40
PRGO's EPS Growth (3Y)(%) is ranked lower than
79% of the 450 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PRGO: -21.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRGO' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.2  Med: 25.70 Max: 210.7
Current: -21.4
-66.2
210.7
» PRGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PRGO Guru Trades in Q2 2014

Alan Fournier 472,300 sh (New)
Paul Tudor Jones 150,000 sh (+8233.33%)
David Rolfe 1,742,399 sh (+16.57%)
John Keeley 30,593 sh (+6.44%)
Vanguard Health Care Fund 3,210,552 sh (+3.76%)
Ron Baron 78,373 sh (+0.65%)
Ken Fisher 486,226 sh (+0.49%)
Steven Cohen 15,000 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
George Soros Sold Out
Mariko Gordon 28,494 sh (-0.09%)
Ruane Cunniff 1,717,063 sh (-0.11%)
» More
Q3 2014

PRGO Guru Trades in Q3 2014

Joel Greenblatt 1,665 sh (New)
Jim Simons 199,308 sh (New)
Steven Cohen 77,300 sh (+415.33%)
Alan Fournier 932,457 sh (+97.43%)
Vanguard Health Care Fund 3,305,652 sh (+2.96%)
David Rolfe 1,788,328 sh (+2.64%)
Ron Baron 79,307 sh (+1.19%)
Robert Bruce 9,926 sh (unchged)
Mariko Gordon 28,494 sh (unchged)
Ruane Cunniff 1,710,706 sh (-0.37%)
John Keeley 30,263 sh (-1.08%)
Ken Fisher 477,504 sh (-1.79%)
Paul Tudor Jones 135,204 sh (-9.86%)
» More
Q4 2014

PRGO Guru Trades in Q4 2014

Louis Moore Bacon 60,000 sh (New)
Ray Dalio 13,900 sh (New)
Steven Cohen 165,800 sh (+114.49%)
Vanguard Health Care Fund 3,855,652 sh (+16.64%)
Alan Fournier 932,457 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Mariko Gordon 28,494 sh (unchged)
Joel Greenblatt Sold Out
Ron Baron 79,004 sh (-0.38%)
Ruane Cunniff 1,699,683 sh (-0.64%)
John Keeley 30,033 sh (-0.76%)
Ken Fisher 465,240 sh (-2.57%)
David Rolfe 1,455,681 sh (-18.60%)
Jim Simons 51,708 sh (-74.06%)
Paul Tudor Jones 1,500 sh (-98.89%)
» More
Q1 2015

PRGO Guru Trades in Q1 2015

Paul Tudor Jones 6,664 sh (+344.27%)
John Keeley 30,731 sh (+2.32%)
David Rolfe 1,485,634 sh (+2.06%)
Robert Bruce 9,926 sh (unchged)
Vanguard Health Care Fund 3,855,652 sh (unchged)
Alan Fournier 932,457 sh (unchged)
Mariko Gordon Sold Out
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
Ruane Cunniff 1,698,713 sh (-0.06%)
Ken Fisher 461,071 sh (-0.90%)
Ron Baron 76,494 sh (-3.18%)
Jim Simons 35,008 sh (-32.30%)
Steven Cohen 110,000 sh (-33.66%)
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Perrigo Co PLC

David Rolfe Comments on Perrigo - Jan 27, 2014

During the quarter, Perrigo (PRGO) announced strong September quarter adjusted earnings growth of 20%.  We say “adjusted” because the Company incurred what we believe are non-recurring charges related to the recent purchase of Elan Corporation, which is a branded-drug company domiciled in Ireland.  Upon the closing of this purchase, Perrigo has “re-domiciled” itself in Ireland, with an effective tax rate meaningfully below what they were subjected to in the U.S.  Given that the Company actively pursues a strategy of inorganic growth as much as it pursues organic growth - having acquired six new businesses over the past 18 months (including Elan) - we expect that this new tax structure should make future acquisitions, particularly those U.S. based businesses, much more attractive.  Further, Perrigo’s core business, which includes private-label over-the-counter (OTC) pharmaceuticals and infant formula, drove much of the year-over-year growth.  The Company’s unrivaled scale in manufacturing and marketing of store-branded offerings continues to enable retailers to mimic the value proposition of OTC pharmaceuticals and infant formula.  This “store-brand conversion” is a multi-year trend that we expect will continue for the foreseeable future as consumers continue to become more value-conscious, yet more comfortable with store-brand quality that Perrigo helps engineer. 

 

From David Rolfe (Trades, Portfolio)’s Wedgewood Partners Fourth Quarter 2013 Commentary.

Check out David Rolfe latest stock trades

Meridian Funds Comments on Perrigo - Aug 28, 2013

Perrigo (PRGO) is a global manufacturer of over-the-counter (OTC) store brand and generic prescription pharmaceuticals, infant formulas, nutritional products and active pharma ingredients. The company is the dominant player in the OTC drug market with the largest distribution network and broadest range of product offerings. The OTC store brands have increased their market share by about 1-2% annually at the expense of national name product given their superior value proposition to both the consumer and retailers. Perrigo has numerous growth drivers over the next few years including the continued penetration of OTC store brands and introduction of new product categories. The stock sells at a reasonable valuation, in our opinion, given the company's strong management team, financial returns and long-term growth prospects.

From Meridian Funds's commentary for the quarter ended June 30, 2013.


Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 119.00
PRGO's P/E(ttm) is ranked lower than
87% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.70 vs. PRGO: 119.00 )
Ranked among companies with meaningful P/E(ttm) only.
PRGO' s 10-Year P/E(ttm) Range
Min: 13.36  Med: 25.11 Max: 135.33
Current: 119
13.36
135.33
Forward P/E 21.23
PRGO's Forward P/E is ranked higher than
57% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.98 vs. PRGO: 21.23 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 119.30
PRGO's PE(NRI) is ranked lower than
87% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.70 vs. PRGO: 119.30 )
Ranked among companies with meaningful PE(NRI) only.
PRGO' s 10-Year PE(NRI) Range
Min: 13.25  Med: 25.05 Max: 135.67
Current: 119.3
13.25
135.67
P/B 2.70
PRGO's P/B is ranked higher than
60% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. PRGO: 2.70 )
Ranked among companies with meaningful P/B only.
PRGO' s 10-Year P/B Range
Min: 2.01  Med: 3.13 Max: 5.96
Current: 2.7
2.01
5.96
P/S 5.95
PRGO's P/S is ranked lower than
70% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.27 vs. PRGO: 5.95 )
Ranked among companies with meaningful P/S only.
PRGO' s 10-Year P/S Range
Min: 0.95  Med: 2.18 Max: 6.44
Current: 5.95
0.95
6.44
PFCF 27.96
PRGO's PFCF is ranked higher than
69% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.86 vs. PRGO: 27.96 )
Ranked among companies with meaningful PFCF only.
PRGO' s 10-Year PFCF Range
Min: 10.63  Med: 25.63 Max: 86.68
Current: 27.96
10.63
86.68
POCF 24.43
PRGO's POCF is ranked higher than
56% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.88 vs. PRGO: 24.43 )
Ranked among companies with meaningful POCF only.
PRGO' s 10-Year POCF Range
Min: 8.66  Med: 18.21 Max: 30.42
Current: 24.43
8.66
30.42
EV-to-EBIT 39.31
PRGO's EV-to-EBIT is ranked lower than
66% of the 482 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.80 vs. PRGO: 39.31 )
Ranked among companies with meaningful EV-to-EBIT only.
PRGO' s 10-Year EV-to-EBIT Range
Min: -6.7  Med: 18.90 Max: 45.7
Current: 39.31
-6.7
45.7
PEG 5.55
PRGO's PEG is ranked lower than
70% of the 249 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. PRGO: 5.55 )
Ranked among companies with meaningful PEG only.
PRGO' s 10-Year PEG Range
Min: 0.67  Med: 0.85 Max: 9.96
Current: 5.55
0.67
9.96
Shiller P/E 60.18
PRGO's Shiller P/E is ranked lower than
71% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.44 vs. PRGO: 60.18 )
Ranked among companies with meaningful Shiller P/E only.
PRGO' s 10-Year Shiller P/E Range
Min: 25  Med: 48.76 Max: 3968
Current: 60.18
25
3968
Current Ratio 3.99
PRGO's Current Ratio is ranked higher than
71% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. PRGO: 3.99 )
Ranked among companies with meaningful Current Ratio only.
PRGO' s 10-Year Current Ratio Range
Min: 1.52  Med: 2.37 Max: 4.05
Current: 3.99
1.52
4.05
Quick Ratio 3.50
PRGO's Quick Ratio is ranked higher than
71% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. PRGO: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
PRGO' s 10-Year Quick Ratio Range
Min: 0.89  Med: 1.31 Max: 3.56
Current: 3.5
0.89
3.56
Days Inventory 87.63
PRGO's Days Inventory is ranked higher than
65% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.04 vs. PRGO: 87.63 )
Ranked among companies with meaningful Days Inventory only.
PRGO' s 10-Year Days Inventory Range
Min: 38.76  Med: 97.24 Max: 108.46
Current: 87.63
38.76
108.46
Days Sales Outstanding 76.32
PRGO's Days Sales Outstanding is ranked lower than
53% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.21 vs. PRGO: 76.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRGO' s 10-Year Days Sales Outstanding Range
Min: 30.17  Med: 59.26 Max: 84.05
Current: 76.32
30.17
84.05

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.25
PRGO's Dividend Yield is ranked lower than
92% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. PRGO: 0.25 )
Ranked among companies with meaningful Dividend Yield only.
PRGO' s 10-Year Dividend Yield Range
Min: 0.22  Med: 0.47 Max: 1.23
Current: 0.25
0.22
1.23
Dividend Payout 0.30
PRGO's Dividend Payout is ranked higher than
56% of the 394 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. PRGO: 0.30 )
Ranked among companies with meaningful Dividend Payout only.
PRGO' s 10-Year Dividend Payout Range
Min: 0.07  Med: 0.13 Max: 0.42
Current: 0.3
0.07
0.42
Dividend growth (3y) 12.60
PRGO's Dividend growth (3y) is ranked higher than
62% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. PRGO: 12.60 )
Ranked among companies with meaningful Dividend growth (3y) only.
PRGO' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 8.30 Max: 49.8
Current: 12.6
0
49.8
Yield on cost (5-Year) 0.46
PRGO's Yield on cost (5-Year) is ranked lower than
82% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. PRGO: 0.46 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PRGO' s 10-Year Yield on cost (5-Year) Range
Min: 0.4  Med: 0.86 Max: 2.25
Current: 0.46
0.4
2.25
Share Buyback Rate -7.30
PRGO's Share Buyback Rate is ranked lower than
71% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.30 vs. PRGO: -7.30 )
Ranked among companies with meaningful Share Buyback Rate only.
PRGO' s 10-Year Share Buyback Rate Range
Min: 1.7  Med: 0.20 Max: -9.8
Current: -7.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.92
PRGO's Price/Projected FCF is ranked higher than
66% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. PRGO: 1.92 )
Ranked among companies with meaningful Price/Projected FCF only.
PRGO' s 10-Year Price/Projected FCF Range
Min: 0.98  Med: 1.61 Max: 2.42
Current: 1.92
0.98
2.42
Price/Median PS Value 2.74
PRGO's Price/Median PS Value is ranked lower than
85% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. PRGO: 2.74 )
Ranked among companies with meaningful Price/Median PS Value only.
PRGO' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 0.61 Max: 2.49
Current: 2.74
0.25
2.49
Price/Peter Lynch Fair Value 9.20
PRGO's Price/Peter Lynch Fair Value is ranked lower than
95% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. PRGO: 9.20 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PRGO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.76  Med: 1.30 Max: 8.29
Current: 9.2
0.76
8.29
Earnings Yield (Greenblatt) (%) 2.50
PRGO's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. PRGO: 2.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRGO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.2  Med: 5.20 Max: 9.7
Current: 2.5
2.2
9.7
Forward Rate of Return (Yacktman) (%) 15.33
PRGO's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.89 vs. PRGO: 15.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PRGO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.8  Med: 5.85 Max: 36.4
Current: 15.33
1.8
36.4

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 5,150 6,096 6,373 7,154
EPS($) 7.21 8.65 9.71 9.85
EPS without NRI($) 7.21 8.65 9.71 9.85

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PRGO.Israel, PIG.Germany,
Perrigo Co PLC was incorporated under the laws of Ireland on June 28, 2013. The Company develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients. The Company is a manufacturer of OTC healthcare products for the store brand market. The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences. The Consumer Healthcare segment is the store brand manufacturer of OTC pharmaceutical products. Its product categories include analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation and animal health; secondary product categories include feminine hygiene, diabetes care and dermatological care. The Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, and vitamin, mineral and dietary supplement products to retailers, distributors and consumers primarily in the U.S., Canada, Mexico and China. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drugs primarily for the U.S. market. it encompasses an array of topical dosage forms such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The Company develops, manufactures, and markets API used worldwide by the generic drug industry and branded pharmaceutical companies. Certain of these ingredients are used in its own pharmaceutical products. The manufacturing of these API occurs primarily in Israel. As a result of the Elan acquisition on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised primarily of assets focused on the treatment of Multiple Sclerosis (Tysabri). Its competitors in the U.S. Consumer Healthcare market are Dr. Reddy's Laboratories, Ltd., Actavis Inc., Ranbaxy Inc., PL Developments, Nipro Corporation, and LNK International, Inc. Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber) and Danone Baby Nutrition. Tysabri competes primarily with Avonex, marketed by Biogen Idec; Betaseron, marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in the U.S. The Company is subject to various environmental laws and regulations.
» More Articles for PRGO

Headlines

Articles On GuruFocus.com
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Mariko Gordon Sells Lumber Liquidators, Western Digital May 19 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Weekly 52-Week Highs Highlight: BLK, HIG, PRGO, NKE Mar 23 2015 
Fournier Finds Time for His Own Investments in the Third Quarter Dec 17 2014 
David Rolfe's Wedgewood Partners Q2 2014 Commentary Jul 15 2014 
David Rolfe Comments on Perrigo Jan 27 2014 
Weekly Insider Sells Highlight: ROC, PRGO, JCI, TEL, DISH Dec 16 2013 

More From Other Websites
[video]Mergers and Acquisitions Boom Will Keep Rolling as Interest Rates Rise Jul 02 2015
History Tells Jacob Gottlieb His Top 3 Large-Cap Positions Beat The Market Jul 01 2015
Top Takeaways From BMO's Specialty Pharma Day Jul 01 2015
A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round Jun 30 2015
Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg Jun 29 2015
Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg Jun 29 2015
MEDIA-Hikma, Mallinckrodt said to bid for Boehringer's Roxane Labs - Bloomberg Jun 29 2015
EU regulators to rule on Mylan bid for Perrigo by July 29 Jun 25 2015
Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Jun 24 2015
Edited Transcript of PRGO presentation 23-Jun-15 3:45pm GMT Jun 24 2015
Perrigo Going Up With Or Without Mylan, Says BMO Jun 23 2015
Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source Jun 23 2015
Teva Announces Acquisition of 4.61% Interest in Mylan - Analyst Blog Jun 22 2015
Teva gains standing to challenge Mylan poison pill Jun 19 2015
Teva takes 4.6 percent stake in Mylan as part of bid Jun 19 2015
Teva takes 4.6 percent stake in Mylan as part of bid Jun 19 2015
Teva Takes 4.6% Stake in Mylan Jun 19 2015
Teva ups Mylan stake, handed setback in court ruling Jun 18 2015
Teva Bid for Mylan Could Be 'Imminent' Jun 18 2015
Mylan Inks Deal with Pulmatrix for Respiratory Disease Drug - Analyst Blog Jun 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK